AYTU BIOPHARMA, INC AYTU
Aytu BioPharma, Inc. ("Aytu," the "Company," "we," "us," or "our") is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. We were originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. In March 2021, we changed our name to Aytu BioPharma, Inc. Our common stock trades on the Nasdaq Capital Market LLC (the "Nasdaq") under the ticker symbol "AYTU." Our principal office is located at 7900 East Union Avenue, Suite 920, Denver, Colorado 80237, and our telephone number is (720) 437-6580.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by segment
- Rx Segment - ADHD Portfolio
- Rx Segment - The Pediatric Portfolio
- Other
| Segment | FY2025 | FY2024 |
|---|---|---|
| Rx Segment - ADHD Portfolio | $57.6M | $57.8M |
| Rx Segment - The Pediatric Portfolio | $8.8M | $7.3M |
| Other | $37.0K | $119.0K |
As the company reported it, from the “Note 3 - Revenue - Disaggregation of Revenue (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M | $27.6M | $7.3M | $3.7M | $3.2M | $2.6M |
| Cost of revenue | $20.6M | $16.1M | $40.8M | $44.4M | $36.4M | $8.3M | $2.2M | $2.1M | $1.4M | $957.1K |
| Gross profit | $45.8M | $49.1M | $66.6M | $52.3M | $29.2M | $19.4M | $5.1M | $1.6M | $1.8M | $1.6M |
| R&D | $1.3M | $2.8M | $4.1M | $12.7M | $5.6M | $1.7M | $589.1K | $167.6K | $959.9K | $6.1M |
| SG&A | $17.4M | $20.0M | $28.6M | $31.2M | $25.5M | $19.7M | $18.9M | $17.7M | $17.4M | $8.5M |
| Total operating expenses | $53.7M | $50.6M | $83.7M | $162.2M | $88.1M | $40.5M | $24.2M | $23.4M | $23.3M | $24.3M |
| Operating income | -$7.8M | -$1.6M | -$17.1M | -$109.9M | -$58.9M | -$21.1M | -$16.8M | -$19.7M | -$20.1M | -$21.7M |
| Interest expense | $3.7M | $5.1M | $5.0M | — | — | $2.6M | $535.5K | $749.4K | $2.5M | $5.5M |
| Pre-tax income | -$13.7M | -$10.4M | -$17.1M | -$108.9M | -$58.0M | -$13.6M | -$27.1M | -$10.2M | -$22.5M | -$28.2M |
| Income tax | $437.0K | $2.1M | $0 | $110.0K | $259.0K | $0 | $0 | $0 | $0 | $0 |
| Net income | -$13.6M | -$15.8M | -$17.1M | -$108.8M | -$58.3M | -$13.6M | -$27.1M | -$10.2M | -$22.5M | -$28.2M |
| EPS, basic | -2.16 | -2.86 | -5.11 | -74.01 | -3.48 | — | — | — | — | — |
| EPS, diluted | — | — | -5.11 | -74.01 | -3.48 | -3.01 | -3.48 | -15.31 | -48.30 | -323.70 |
| Shares, diluted (wtd. avg.) | 6.3M | 5.5M | 3.3M | 1.5M | 16.7M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $31.0M | $20.0M | $23.0M | $19.4M | $49.9M | $48.3M | $11.0M | $7.0M | $802.3K | $8.1M |
| Short-term investments | — | — | — | — | — | — | — | — | $0 | $1.0M |
| Receivables | $31.2M | $23.5M | $28.9M | $21.7M | $28.2M | $5.6M | $1.7M | $578.8K | $528.0K | $162.4K |
| Inventory | $11.4M | $12.1M | $12.0M | $10.8M | $16.3M | $10.0M | $1.4M | $1.3M | $1.3M | $524.7K |
| Total current assets | $79.2M | $61.9M | $72.8M | $59.9M | $105.2M | $75.4M | $15.4M | $9.5M | $3.0M | $10.1M |
| Property, plant and equipment | $532.0K | $693.0K | $1.8M | — | — | $258.5K | $203.7K | $218.7K | $647.3K | $231.4K |
| Goodwill | — | — | $0 | $0 | $65.8M | $28.1M | $0 | — | $238.4K | $221.0K |
| Other intangibles | $42.2M | $52.5M | $59.0M | $70.6M | $85.5M | $48.9M | $19.1M | $245.9K | $271.3K | $296.6K |
| Total assets | $124.2M | $118.1M | $136.5M | $137.6M | $265.7M | $153.3M | $34.7M | $21.1M | $15.0M | $24.3M |
| Accounts payable | $10.6M | $10.3M | $13.5M | — | $19.3M | $11.6M | $2.1M | $2.1M | $2.2M | $2.3M |
| Short-term debt | $1.9M | $1.9M | $85.0K | $3.8M | — | $982.1K | $0 | — | — | — |
| Total current liabilities | $63.1M | $62.2M | $69.0M | $64.4M | $109.4M | $28.8M | $5.4M | $3.4M | $3.6M | $10.1M |
| Long-term debt | $10.9M | $10.9M | $14.7M | $15.0M | — | — | — | — | — | — |
| Total liabilities | — | — | $97.1M | $93.3M | $128.1M | $58.3M | $27.6M | $7.6M | $11.0M | $14.3M |
| Retained earnings | -$333.5M | -$320.0M | -$304.1M | -$287.1M | -$178.3M | -$120.0M | -$106.4M | -$79.3M | -$69.1M | -$46.6M |
| Total equity | $19.0M | $27.7M | $39.4M | $44.3M | $137.6M | $95.0M | $7.1M | $13.4M | $4.0M | $10.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.9M | -$1.4M | -$5.1M | -$28.8M | -$26.0M | -$28.4M | -$13.8M | -$15.9M | -$13.8M | -$10.7M |
| Depreciation and amortisation | $5.4M | $6.7M | $8.8M | $10.1M | $9.2M | $5.7M | $2.7M | $2.6M | $4.4M | $874.8K |
| Stock-based compensation | $576.0K | $2.4M | $6.0M | $5.2M | $3.6M | $1.1M | $1.0M | $596.9K | $2.5M | $902.9K |
| Capital expenditure | $228.0K | $329.0K | — | $0 | $2.3M | $0 | $59.8K | $74.7K | $111.6K | $252.9K |
| Investing cash flow | -$2.6M | -$329.0K | -$117.0K | -$3.2M | -$2.8M | -$5.7M | -$1.1M | -$484.3K | -$3.5M | -$5.3M |
| Financing cash flow | $15.4M | -$1.3M | $8.9M | $1.5M | $30.3M | $71.1M | $19.1M | $22.7M | $10.2M | $16.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-25-029723.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M | $3.2M | $3.7M | $7.3M | $27.6M | $65.6M | $96.7M | $107.4M | $65.2M | $66.4M |
| Gross profit | $1.6M | $1.8M | $1.6M | $5.1M | $19.4M | $29.2M | $52.3M | $66.6M | $49.1M | $45.8M |
| Net income | -$28.2M | -$22.5M | -$10.2M | -$27.1M | -$13.6M | -$58.3M | -$108.8M | -$17.1M | -$15.8M | -$13.6M |
Recent filings and events
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |